Safety of a short-term infusion of fosnetupitant in patients with gastrointestinal and breast cancer: a prospective study.
Akinobu NakataNaoya HashimotoYukiya NaritaMunehiro WakabayashiHiroyuki KodamaTakatsugu OgataKazunori HondaToshiki MasuishiHiroya TaniguchiShigenori KadowakiMasashi AndoYuka EndoHaruru KotaniAyumi KataokaMasaya HattoriAkiyo YoshimuraMasataka SawakiKazuki NozawaIsao OzeHiroji IwataKei MuroPublished in: The oncologist (2024)
Short-term infusion of fosnetupitant, administered over 15 minutes, was demonstrated to be safe and effective for patients receiving HEC or MEC (Japan Registry of Clinical Trials Trial ID: jRCT1041220144).